David Hollander - 01 Sep 2026 Form 4 Insider Report for Veradermics, Inc (MANE)

Reporting relationship: Chief R&D Officer
Issuer ticker: MANE
Reported as of: 01 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Sep 2026, 16:35:03 UTC
Prior SEC filing: 20 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Greco, Attorney-in-Fact

Key filing fact

David Hollander filed Form 4 for Veradermics, Inc (MANE) on 03 Sep 2026.

Key facts

This page summarizes David Hollander's Form 4 filing for Veradermics, Inc (MANE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Sep 2026, 16:35.

Change

Previous filing in this sequence was filed on 20 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001793796 Primary reporting owner

Hollander David

Relationship: Chief R&D Officer
Address: 470 JAMES ST., NEW HAVEN
Signature: /s/ Michael Greco, Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MANE transaction

Common Stock

Award

Transaction value
Shares: +9,650
Change %
Price: $0.000000^*
Shares after: 9,650
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MANE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +19,300
Change %
Price: $0.000000^*
Shares after: 19,300
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,300
Exercise price: $97.51
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service.

Footnote F2

The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.